ReviewBlood cancer journal2022
Cutaneous manifestations of monoclonal gammopathy.
Review in Blood cancer journal, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 48 citations in OpenAlex.
- Monoclonal Gammopathy of Thrombotic Significance.American journal of hematology · 2026Review
- Monoclonal gammopathy of clinical significance: a multisystem review.Blood cancer journal · 2026Review
- Article
- Necrobiotic xanthogranuloma: Highlighting the role of clinicopathologic correlation in an atypical presentation.Dermatology online journal · 2026Article
- Immune-mediated multisystem injury associated with monoclonal gammopathy of clinical significance: a case report.Frontiers in immunology · 2026Article
- Cutaneous light chain amyloidosis and erythema elevatum diutinum as the presenting features of IgA monoclonal gammopathy: a rare case report and comprehensive literature review.Annals of hematology · 2025Review
- Article
- Paraneoplastic leukocytoclastic vasculitis mimicking ulcus cruris as rare initial manifestation of smoldering myeloma IgG kappa.Annals of hematology · 2025Article
- [Chinese expert consensus on screening and clinical application of monoclonal immunoglobulins(2025)].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2025Article
- Review
- M-protein-related necrobiotic granuloma in a multiple myeloma patient treated with daratumumab, lenalidomide and dexamethasone.British journal of haematology · 2025Article
- Hypergammaglobulinemia in Hidradenitis Suppurativa Patients: A New Emerging Association.Clinical, cosmetic and investigational dermatology · 2025Article
- POEMS syndrome presenting withFrontiers in medicine · 2025Article
- Classical complement activation in light and heavy chain deposition disease with acquired cutis laxa and bronchiolitis obliterans: a case report of monoclonal gammopathy of clinical significance.Frontiers in immunology · 2025Article
- Dermatologic manifestations of hematologic disorders.Annals of hematology · 2024Review
- Population-based screening cohort study reveals no association between monoclonal gammopathy of undetermined significance (MGUS), smoldering multiple myeloma (SMM), multiple myeloma (MM), and alopecia.Archives of dermatological research · 2024Article
- Monoclonal gammopathy in the setting of Pyoderma gangrenosum.Archives of dermatological research · 2024Article
- Cutaneous involvement of light chain deposition disease: A case report.SAGE open medical case reports · 2024Article
- Monoclonal gammopathy of increasing significance: time to screen?Haematologica · 2023Review
- Prevalence of MGCS Among Patients With Monoclonal Gammopathies.HemaSphere · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Monoclonal gammopathy associated with dermatological manifestations are a well-recognized complication. These skin disorders can be associated with infiltration and proliferation of a malignant plasma cells or by a deposition of the monoclonal immunoglobulin in a nonmalignant monoclonal gammopathy. These disorders include POEMS syndrome, light chain amyloidosis, Schnitzler syndrome, scleromyxedema and TEMPI syndrome. This article provides a review of clinical manifestations, diagnostics criteria, natural evolution, pathogenesis, and treatment of these cutaneous manifestations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.